Azimi Manavi Behnaz, Stuart Amanda L, Pasco Julie A, Hodge Jason M, Samarasinghe Rasika M, Weerasinghe D Kavindi, Williams Lana J
School of Medicine, IMPACT-The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC, Australia.
Barwon Health, Geelong, VIC, Australia.
Front Psychiatry. 2023 Jan 5;13:1004366. doi: 10.3389/fpsyt.2022.1004366. eCollection 2022.
Schizophrenia has been shown to be associated with reduced bone mineral density (BMD) and higher fracture risk. However, less is known whether antipsychotic treatment is associated with reduced BMD. Thus, we aimed to examine associations between antipsychotic use and BMD among men and women drawn from the general population.
This cross-sectional study involved 793 women and 587 men enrolled in the Geelong Osteoporosis Study (GOS). BMD was determined using dual-energy X-ray absorptiometry at the spine and hip. Information regarding socio-economic status (SES), current medication and/or supplementation use, lifestyle factors, and anthropometry was collected. Association between antipsychotic use and BMD was determined using linear regression after adjusting for potential confounders.
Of the group, 33 women (4.2%) and 16 men (2.7%) currently used antipsychotics. Age was identified as an effect modifier in the association between antipsychotic use and BMD for women. Amongst women aged < 60 years, adjusted mean BMD was 11.1% lower at the spine [1.139 (95%CI 1.063-1.216) vs. 1.250 (95%CI 1.223-1.277) g/cm, = 0.005] for antipsychotic users compared to non-users. At the hip, age, weight, and smoking adjusted mean BMD was 9.9% lower [0.893 (95%CI 0.837-0.950) vs. 0.992 (95%CI 0.976-1.007) g/cm, < 0.001] for antipsychotic users in comparison with non-users. The pattern persisted following further adjustments. There was no association detected between antipsychotic use and BMD for women aged 60 years and over and for men.
Our data suggest that antipsychotic medication use is associated with reduced BMD in younger women but not older women or men.
精神分裂症已被证明与骨密度(BMD)降低及骨折风险升高有关。然而,对于抗精神病药物治疗是否与骨密度降低相关,人们了解较少。因此,我们旨在研究普通人群中男性和女性使用抗精神病药物与骨密度之间的关联。
这项横断面研究纳入了吉朗骨质疏松症研究(GOS)中的793名女性和587名男性。采用双能X线吸收法测定脊柱和髋部的骨密度。收集了社会经济地位(SES)、当前用药和/或补充剂使用情况、生活方式因素及人体测量学等信息。在对潜在混杂因素进行校正后,使用线性回归确定抗精神病药物使用与骨密度之间的关联。
在该组中,33名女性(4.2%)和16名男性(2.7%)目前正在使用抗精神病药物。年龄被确定为女性使用抗精神病药物与骨密度之间关联的效应修饰因素。在年龄小于60岁的女性中,与未使用抗精神病药物者相比,使用抗精神病药物者脊柱的校正平均骨密度低11.1%[1.139(95%CI 1.063 - 1.216)vs. 1.250((95%CI 1.223 - 1.277)g/cm²,P = 0.005]。在髋部,经年龄、体重和吸烟校正后,使用抗精神病药物者的平均骨密度比未使用者低9.9%[0.893(95%CI 0.837 - 0.950)vs. 0.992(95%CI 0.976 - 1.007)g/cm²,P < 0.001]。进一步校正后该模式依然存在。在60岁及以上的女性和男性中,未检测到抗精神病药物使用与骨密度之间存在关联。
我们的数据表明,使用抗精神病药物与年轻女性骨密度降低有关,但与老年女性或男性无关。